{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T13:40:44Z","timestamp":1712324444695},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2011,3,1]],"date-time":"2011-03-01T00:00:00Z","timestamp":1298937600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Sci. China Life Sci."],"published-print":{"date-parts":[[2011,3]]},"DOI":"10.1007\/s11427-011-4143-4","type":"journal-article","created":{"date-parts":[[2011,3,25]],"date-time":"2011-03-25T19:24:59Z","timestamp":1301081099000},"page":"255-262","source":"Crossref","is-referenced-by-count":6,"title":["Antitumor effects of an engineered and energized fusion protein consisting of an anti-CD20 scFv fragment and lidamycin"],"prefix":"10.1007","volume":"54","author":[{"given":"Hong","family":"Fang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"QingFang","family":"Miao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"ShengHua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"DongSheng","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"YongSu","family":"Zhen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,3,16]]},"reference":[{"key":"4143_CR1","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1023\/A:1008416911099","volume":"9","author":"N. L. Berinstein","year":"1998","unstructured":"Berinstein N L, Grillo-Lopez A J, White C A, et al. Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin\u2019s lymphoma. Ann Oncol, 1998, 9: 995\u20131001, 9818074, 10.1023\/A:1008416911099, 1:STN:280:DyaK1M%2FjsFCgtg%3D%3D","journal-title":"Ann Oncol"},{"key":"4143_CR2","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/sj.gt.3302705","volume":"13","author":"T. Meerten Van","year":"2006","unstructured":"Van Meerten T, Claessen M J, Hagenbeek A. The CD20\/a CD20 \u2019suicide\u2019 system: novel vectors with improved safety and expression profiles and efficient elimination of CD20-transgenic T cells. Gene Ther, 2006, 13: 789\u2013797, 16421601, 10.1038\/sj.gt.3302705","journal-title":"Gene Ther"},{"key":"4143_CR3","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1053\/sonc.2002.30156","volume":"29","author":"D. G. Maloney","year":"2002","unstructured":"Maloney D G, Smith B, Rose A. Rituximab: mechanism of action and resistance. Semin Oncol, 2002, 29: 2\u20139, 11842383, 10.1053\/sonc.2002.30156, 1:CAS:528:DC%2BD38XhvFKksb4%3D","journal-title":"Semin Oncol"},{"key":"4143_CR4","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1111\/j.1365-2141.2008.07383.x","volume":"143","author":"C. Gisselbrecht","year":"2008","unstructured":"Gisselbrecht C. Use of rituximab in diffuse large B-cell lymphoma in the salvage setting. Br J Haematol. 2008, 143: 607\u2013621, 18950460, 10.1111\/j.1365-2141.2008.07383.x, 1:CAS:528:DC%2BD1MXlvF2ktg%3D%3D","journal-title":"Br J Haematol."},{"key":"4143_CR5","doi-asserted-by":"crossref","first-page":"3629","DOI":"10.1038\/sj.onc.1210365","volume":"26","author":"B. Bonavida","year":"2007","unstructured":"Bonavida B. Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo\/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions. Oncogene, 2007, 26: 3629\u20133636, 17530016, 10.1038\/sj.onc.1210365, 1:CAS:528:DC%2BD2sXlslCqsLo%3D","journal-title":"Oncogene"},{"key":"4143_CR6","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1111\/j.1749-6632.2009.04804.x","volume":"1173","author":"J. Polido-Pereira","year":"2009","unstructured":"Polido-Pereira J, Ferreira D, Rodrigues A M. Rituximab use in pediatric autoimmune diseases: four case reports. Ann N Y Acad Sci, 2009, 1173: 712\u2013720, 19758220, 10.1111\/j.1749-6632.2009.04804.x","journal-title":"Ann N Y Acad Sci"},{"key":"4143_CR7","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.1742-7843.2009.00452.x","volume":"106","author":"R. Korhonen","year":"2010","unstructured":"Korhonen R, Moilanen E. Anti-CD20 antibody rituximab in the treatment of rheumatoid arthritis. Basic Clin Pharmacol Toxicol, 2010, 106: 13\u201321, 19686542, 1:CAS:528:DC%2BC3cXntFyl","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"4143_CR8","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s10067-010-1387-5","volume":"29","author":"E. Murray","year":"2010","unstructured":"Murray E, Perry M. Off-label use of rituximab in systemic lupus erythematosus: a systematic review. Clin Rheumatol, 2010, 29: 707\u2013716, 20155295, 10.1007\/s10067-010-1387-5","journal-title":"Clin Rheumatol"},{"key":"4143_CR9","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/j.1756-185X.2009.01438.x","volume":"12","author":"N. L. Lui","year":"2009","unstructured":"Lui N L, Thumboo J, Fong K Y. A case of refractory vasculitic ulcers in a systemic lupus erythematosus patient responding to rituximab and hyperbaric oxygen therapy. Int J Rheum Dis, 2009, 12: 366\u2013369, 20374378, 10.1111\/j.1756-185X.2009.01438.x","journal-title":"Int J Rheum Dis"},{"key":"4143_CR10","first-page":"495","volume":"144","author":"M. Troiano","year":"2009","unstructured":"Troiano M, Lotti T. Rituximab in dermatological diseases. G Ital Dermatol Venereol, 2009, 144: 495\u2013499, 19755955, 1:STN:280:DC%2BD1Mnis1yhtQ%3D%3D","journal-title":"G Ital Dermatol Venereol"},{"key":"4143_CR11","first-page":"65","volume":"10","author":"X. F. Yang","year":"1990","unstructured":"Yang X F, Shen D C, Jin Y G, et al. Preparation and characterization of a monoclonal antibody HI47 direct to human B lymphocyte (in Chinese). Curr Immunol, 1990, 10: 65","journal-title":"Curr Immunol"},{"key":"4143_CR12","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1002\/(SICI)1097-0290(19980820)59:4<517::AID-BIT15>3.0.CO;2-6","volume":"59","author":"J. S. Harrison","year":"1998","unstructured":"Harrison J S, Gill A, Hoare M. Stability of a single-chain Fv antibody fragment when exposed to a high shear environment combined with air-liquid interfaces. Biotechnol Bioeng, 1998, 59: 517\u2013519, 10099366, 10.1002\/(SICI)1097-0290(19980820)59:4<517::AID-BIT15>3.0.CO;2-6, 1:CAS:528:DyaK1cXkvVKntLc%3D","journal-title":"Biotechnol Bioeng"},{"key":"4143_CR13","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.7164\/antibiotics.42.1294","volume":"42","author":"Y. S. Zhen","year":"1989","unstructured":"Zhen Y S, Ming X Y, Yu B, et al. A new macromolecular antitumor antibiotic, C-1027. III. Antitumor activity. J Antibiot (Tokyo), 1989, 42: 1294\u20131298, 1:CAS:528:DyaL1MXlsVKnsrs%3D","journal-title":"J Antibiot (Tokyo)"},{"key":"4143_CR14","doi-asserted-by":"crossref","first-page":"50","DOI":"10.2174\/1874467210801010050","volume":"1","author":"R. G. Shao","year":"2008","unstructured":"Shao R G. Pharmacology and therapeutic applications of enediyne antitumor antibiotics. Curr Mol Pharmacol, 2008, 1: 50\u201360, 20021423, 10.2174\/1874467210801010050, 1:CAS:528:DC%2BD1cXis12nt78%3D","journal-title":"Curr Mol Pharmacol"},{"key":"4143_CR15","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2174\/187152008783497055","volume":"8","author":"R. G. Shao","year":"2008","unstructured":"Shao R G, Zhen Y S. Enediyne anticancer antibiotic lidamycin: chemistry, biology and pharmacology. Anticancer Agents Med Chem, 2008, 8: 123\u2013131, 18288918, 10.2174\/187152008783497055, 1:CAS:528:DC%2BD1cXhsFOmsLc%3D","journal-title":"Anticancer Agents Med Chem"},{"key":"4143_CR16","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1038\/aps.2009.75","volume":"30","author":"Y. Z. Zhen","year":"2009","unstructured":"Zhen Y Z, Lin Y J, Li Y, et al. Lidamycin shows highly potent cytotoxic to myeloma cells and inhibits tumor growth in mice. Acta Pharmacol Sin, 2009, 30: 1025\u20131032, 19575006, 10.1038\/aps.2009.75, 1:CAS:528:DC%2BD1MXotVaqt74%3D","journal-title":"Acta Pharmacol Sin"},{"key":"4143_CR17","first-page":"601","volume":"43","author":"S. H. Zhang","year":"2008","unstructured":"Zhang S H, Chen J, Jiang M, et al. Lidamycin induces apoptosis of human gastric carcinoma BGC823 cells and inhibits xenograft growth in nude mice (in Chinese). Acta Pharma Sin, 2008, 43: 601\u2013604, 1:CAS:528:DC%2BD1cXpslGrs7w%3D","journal-title":"Acta Pharma Sin"},{"key":"4143_CR18","first-page":"336","volume":"30","author":"R. G. Shao","year":"1995","unstructured":"Shao R G, Zhen Y S. Relationship between the molecular composition of C1027, a new macromolecular antibiotic with enediyne chromophore, and its antitumor activity (in Chinese). Acta Pharma Sin, 1995, 30: 336\u2013342, 1:CAS:528:DyaK2MXms1Gkt7c%3D","journal-title":"Acta Pharma Sin"},{"key":"4143_CR19","first-page":"641","volume":"24","author":"X. J. Liu","year":"2005","unstructured":"Liu X J, Dai Y, Shang Y, et al. Inhibitory effect of lidamycin on growth of colon carcinoma 26 and hepatic metastasis in mice (in Chinese). Ai Zheng, 2005, 24: 641\u2013645, 15946470","journal-title":"Ai Zheng"},{"key":"4143_CR20","first-page":"189","volume":"20","author":"R. J. Gao","year":"2007","unstructured":"Gao R J, Liang Y X, Li D D. Effect of lidamycin on telomerase activity in human hepatoma BEL-7402 cells. Biomed Environ Sci, 2007, 20: 189\u2013197, 17672208, 1:CAS:528:DC%2BD2sXotlWiuro%3D","journal-title":"Biomed Environ Sci"},{"key":"4143_CR21","doi-asserted-by":"crossref","first-page":"3980","DOI":"10.3748\/wjg.v11.i26.3980","volume":"11","author":"Y. H. Huang","year":"2005","unstructured":"Huang Y H, Shang B Y, Zhen Y S. Antitumor efficacy of lidamycin on hepatoma and active moiety of its molecule. World J Gastroenterol, 2005, 11: 3980\u20133984, 15996019, 1:CAS:528:DC%2BD2MXhtVemsLjK","journal-title":"World J Gastroenterol"},{"key":"4143_CR22","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/CAD.0b013e3280112779","volume":"18","author":"Q. F. Miao","year":"2007","unstructured":"Miao Q F, Liu X Y, Shang B Y, et al. An enediyne-energized single-domain antibody-containing fusion protein shows potent antitumor activity. Anticancer Drugs, 2007, 18: 127\u2013137, 17159599, 10.1097\/CAD.0b013e3280112779, 1:CAS:528:DC%2BD28Xht12mtLzN","journal-title":"Anticancer Drugs"},{"key":"4143_CR23","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.exphem.2006.02.015","volume":"34","author":"L. Fischer","year":"2006","unstructured":"Fischer L, Penack O, Gentilini C, et al. The anti-lymphoma effect of antibody-mediated immunotherapy is based on an increased degranulation of peripheral blood natural killer (NK) cells. Exp Hematol, 2006, 34: 753\u2013759, 16728280, 10.1016\/j.exphem.2006.02.015, 1:CAS:528:DC%2BD28XkvVyntLs%3D","journal-title":"Exp Hematol"},{"key":"4143_CR24","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/01.moh.0000141927.77393.39","volume":"11","author":"A. A. Loosdrecht Van de","year":"2004","unstructured":"Van de Loosdrecht A A, Huijgens P C, Ossenkoppele G J. Antibody-targeted therapy: a paradigm of innovative treatment strategies in indolent and aggressive B-cell non-Hodgkin\u2019s lymphoma. Curr Opin Hematol, 2004}, 11}: 419\u2013, 15548997, 10.1097\/01.moh.0000141927.77393.39","journal-title":"Curr Opin Hematol"},{"key":"4143_CR25","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1158\/1078-0432.CCR-06-1860","volume":"13","author":"J. G. Berdeja","year":"2007","unstructured":"Berdeja J G, Hess A, Lucas D M, et al. Systemic interleukin-2 and adoptive transfer of lymphokine-activated killer cells improves antibody-dependent cellular cytotoxicity in patients with relapsed B-cell lymphoma treated with rituximab. Clin Cancer Res, 2007, 13: 2392\u20132399, 17438098, 10.1158\/1078-0432.CCR-06-1860, 1:CAS:528:DC%2BD2sXkt1enu78%3D","journal-title":"Clin Cancer Res"},{"key":"4143_CR26","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/BF00689274","volume":"27","author":"Y. J. Xu","year":"1990","unstructured":"Xu Y J, Li D D, Zhen Y S. Mode of action of C-1027, a new macromolecular antitumor antibiotic with highly potent cytotoxicity, on human hepatoma BEL-7402 cells. Cancer Chemoth Pharm, 1990, 27: 41\u201346, 10.1007\/BF00689274, 1:CAS:528:DyaK3MXhvF2itb8%3D","journal-title":"Cancer Chemoth Pharm"},{"key":"4143_CR27","doi-asserted-by":"crossref","first-page":"417","DOI":"10.7164\/antibiotics.43.417","volume":"43","author":"Y. Sugimoto","year":"1990","unstructured":"Sugimoto Y, Otani T, Oie S, et al. Mechanism of action of a new macromolecular antitumor antibiotic, C-1027. J Antibiot (Tokyo), 1990, 43: 417\u2013421, 1:CAS:528:DyaK3cXktVSht7c%3D","journal-title":"J Antibiot (Tokyo)"},{"key":"4143_CR28","doi-asserted-by":"crossref","first-page":"3280","DOI":"10.4049\/jimmunol.172.5.3280","volume":"172","author":"A. D. Kennedy","year":"2004","unstructured":"Kennedy A D, Beum P V, Solga M D, et al. Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia. J Immunol, 2004, 172: 3280\u20133288, 14978136, 1:CAS:528:DC%2BD2cXhsVCqsbs%3D","journal-title":"J Immunol"},{"key":"4143_CR29","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1023\/A:1006341717398","volume":"18","author":"R. O. Dillman","year":"1999","unstructured":"Dillman R O. Infusion reactions associated with the therapeutic use of monoclonal antibodies in the treatment of malignancy. Cancer Metastasis Rev, 1999, 18: 465\u2013471, 10855789, 10.1023\/A:1006341717398, 1:CAS:528:DC%2BD3cXksFSqsLo%3D","journal-title":"Cancer Metastasis Rev"},{"key":"4143_CR30","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1158\/0008-5472.CAN-08-2753","volume":"69","author":"T. A. Beerman","year":"2009","unstructured":"Beerman T A, Gawron L S, Shin S, et al. C-1027, a radiomimetic enediyne anticancer drug, preferentially targets hypoxic cells. Cancer Res, 2009, 69: 593\u2013598, 19147573, 10.1158\/0008-5472.CAN-08-2753, 1:CAS:528:DC%2BD1MXltFShtw%3D%3D","journal-title":"Cancer Res"}],"container-title":["Science China Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11427-011-4143-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11427-011-4143-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11427-011-4143-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T12:47:50Z","timestamp":1712321270000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11427-011-4143-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,3]]}},"alternative-id":["4143"],"URL":"https:\/\/doi.org\/10.1007\/s11427-011-4143-4","relation":{},"ISSN":["1674-7305","1869-1889"],"issn-type":[{"value":"1674-7305","type":"print"},{"value":"1869-1889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,3]]}}}